Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Ratio of judged-time-to-collision to actual-time-to-collision for threatening versus non-threatening stimuli after oral vasopressin administration
研究概览
简要总结
The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.
详细描述
Animal models and initial findings in humans suggest a role of the AVP signaling system in socio-emotional processes. At the same time, the visual system's remarkable ability to perceive and interpret impending threats, notably through the "looming" phenomenon- a distinct pattern of optical expansion on the retina as objects approach, theoretically allows for precise estimation of the time-to-collision (TTC). It was recently demonstrated that the affective content of looming stimuli influences perceived TTC, with threatening objects judged as approaching sooner than non-threatening objects, hinting at a nuanced interaction between emotional valence and temporal perception. Within this context the present study aims to validate the effects of orally administered on the perception of time-to-collision of threatening and non-threatening stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of vasopressin (20 IU) or placebo before performing a looming visual stimuli task 45 minutes after administration. The task paradigm will encompass threatening (butterfly, rabbit) and non-threatening (spider, snake) stimuli
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
盲法说明
Randomized placebo-controlled double-blind between-subject design
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.
- •Normal or corrected-normal version
排除标准
- •History of neuropsychiatric diseases.
- •History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
- •History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
- •History of renal diseases, including renal stones or renal failure.
- •History of hyponatremia(Serum sodium <135mmol/L) or hyperkalemia (Serum potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
- •Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
- •Infections such as COVID-19 or influenza, or unexplained fever.
- •Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
- •History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.
研究组 & 干预措施
Vasopressin group
Drug: Vasopressin (20IU)
干预措施: Vasopressin (Drug)
Placebo group
Drug: Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Ratio of judged-time-to-collision to actual-time-to-collision for threatening versus non-threatening stimuli after oral vasopressin administration
时间窗: 75 minutes - 105 minutes after treatment
Comparison of the ratio between the judged time to collision and the actual time to collision between the treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.
次要结局
- Fixation duration(ms) for threatening versus non-threatening stimuli after oral vasopressin administration(75 minutes - 105 minutes after treatment)
- First saccade latency(ms) for threatening versus non-threatening stimuli after oral vasopressin administration(75 minutes - 105 minutes after treatment)
研究者
Benjamin Becker
Professor
University of Electronic Science and Technology of China